Want to see DBVT full AI Analyst Report?
DBVT Stock Chart & Stats
$21.34
$0.34(9.80%)
At close: 4:00 PM EST
$21.34
$0.34(9.80%)
Day’s Range― - ―
52-Week Range$8.50 - $26.19
Previous CloseN/A
Volume52.91K
Average Volume (3M)240.72K
Market Cap
$951.96M
Enterprise Value$343.87M
Total Cash (Recent Filing)$229.20M
Total Debt (Recent Filing)$16.30M
Price to Earnings (P/E)―
Beta0.04
Next Earnings
Jul 29, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.93
Shares Outstanding59,212,300
10 Day Avg. Volume283,359
30 Day Avg. Volume240,724
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)9.81
Price to Sales (P/S)0.00
P/FCF Ratio-13.67
Enterprise Value/Market Cap0.36
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-19.77
Enterprise Value/Ebitda-2.16
Forecast
1Y Price Target
$40.97Price Target Upside91.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.8
Revenue Forecast (FY)$4.36M
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageModest debt and a meaningful equity increase strengthen the company’s capital cushion, reducing near-term refinancing pressure. This provides structural flexibility to fund regulatory activities and development programs over the next several months without immediate reliance on heavy new borrowing.
Constructive FDA EngagementOngoing, iterative collaboration with the FDA that resulted in no new data requests materially lowers regulatory execution risk. Guidance focused on organization/formatting reduces scope uncertainty and makes the planned Q3 2026 BLA submission a structurally more achievable milestone toward potential commercialization.
Governance And Capital FlexibilityBoard- and shareholder-approved governance changes and broad capital authorizations provide durable strategic options—succession clarity, financing tools, M&A and incentive capacity—that increase management’s ability to secure funding or strategic partners needed to advance filing and commercialization plans.
Bears Say
No Meaningful RevenueAn absence of commercial revenue means the business is entirely development-stage and must rely on financing or partnerships to sustain operations. Without near-term product sales, the company remains exposed to funding risk until regulatory approval and commercialization generate recurring cash flows.
Sustained Cash BurnConsistently large negative operating and free cash flows imply recurring funding needs and narrow runway absent new capital or revenue. Though free cash flow improved versus prior period, the absolute outflow remains substantial and creates structural financing dependency over the coming months.
Persistent Large Net LossesDeep and persistent net losses erode shareholder value and produce negative returns metrics (TTM ROE ~ -1.89). Losses closely track cash outflows, meaning profitability shortfalls translate into real financing needs and potential dilution unless offset by approval, partnerships, or new funding.
DBV Technologies SA - American News
DBVT FAQ
What was DBV Technologies S.A. - American Depositary Shares’s price range in the past 12 months?
DBV Technologies S.A. - American Depositary Shares lowest stock price was $8.50 and its highest was $26.18 in the past 12 months.
What is DBV Technologies S.A. - American Depositary Shares’s market cap?
DBV Technologies S.A. - American Depositary Shares’s market cap is $951.96M.
When is DBV Technologies S.A. - American Depositary Shares’s upcoming earnings report date?
DBV Technologies S.A. - American Depositary Shares’s upcoming earnings report date is Jul 29, 2026 which is in 27 days.
How were DBV Technologies S.A. - American Depositary Shares’s earnings last quarter?
DBV Technologies S.A. - American Depositary Shares released its earnings results on Apr 30, 2026. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.134 by $0.024.
Is DBV Technologies S.A. - American Depositary Shares overvalued?
According to Wall Street analysts DBV Technologies S.A. - American Depositary Shares’s price is currently Undervalued.
Does DBV Technologies S.A. - American Depositary Shares pay dividends?
DBV Technologies S.A. - American Depositary Shares does not currently pay dividends.
What is DBV Technologies S.A. - American Depositary Shares’s EPS estimate?
DBV Technologies S.A. - American Depositary Shares’s EPS estimate is -0.11.
How many shares outstanding does DBV Technologies S.A. - American Depositary Shares have?
DBV Technologies S.A. - American Depositary Shares has 59,212,300 shares outstanding.
What happened to DBV Technologies S.A. - American Depositary Shares’s price movement after its last earnings report?
DBV Technologies S.A. - American Depositary Shares reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.134. Following the earnings report the stock price went down -5.381%.
Which hedge fund is a major shareholder of DBV Technologies S.A. - American Depositary Shares?
Currently, no hedge funds are holding shares in DBVT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DBV Technologies SA - American Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$40.97 (91.98% Upside)
$40.97 (91.98% Upside)
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.1%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
80.18%
12-Months-Change
Fundamentals
Return on Equity
-130.06%
Trailing 12-Months
Asset Growth
426.88%
Trailing 12-Months
Company Description
DBV Technologies S.A. - American Depositary Shares
DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen's egg allergy. Additionally, DBV Technologies is developing a booster vaccine targeting Bordetella pertussis. Beyond these, the company explores earlier-stage research for a respiratory syncytial virus vaccine and potential therapies for Crohn's disease, celiac disease, and type I diabetes. In partnership with Nestlé Health Science, it is developing MAG1C, a user-friendly atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers. DBV Technologies S.A. was established in 2002.
DBVT Stock 12 Month Forecast
Average Price Target
$40.97
▲(91.98% Upside)
Technical Analysis
Larimar Therapeutics
―
Korro Bio
―
4D Molecular Therapeutics
―
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
62.50% Insiders
2.44% Mutual Funds
32.54% Other Institutional Investors
2.45% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---